Back to results
US 8,541,445 B2Granted
Pyrazolopyridines
AssigneeVertex Pharmaceuticals Incorporated
InventorsJuan-Miguel Jimenez, Philip Collier
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Claims17
A compound represented by structural formula I or IA:
- or a pharmaceutically acceptable salt thereof wherein:
- each ring A is independently a five membered heteroaromatic ring,
- ring B is five- or six-membered saturated carbocyclic or heterocyclic ring;
- R2 is —H, —(CR++2)nCN, —(CR++2)nC(O)N(R*)2, —(CR++2)nOR*, —(CR++2)nN(R*)2, —(CR++2)nN(R*)C(O)R*, or C1-10 aliphatic optionally substituted with one or more halogen, or phenyl;
- each R3 and R4 independently are —H, halogen, C1-10 aliphatic, heterocyclyl, heterocyclylalkyl, aryl, or aralkyl, wherein R3 and R4 are optionally and independently substituted with one or more selected from the group consisting of C1-10 alkyl, halogen, —CN, —NO2, —N(R*)2, —S(O)pR*, —S(O)pNR*, —C(O)N(R*)2, —NR*C(O), —OC(O)N(R*)2, —N(R*)C(O)OR*, —N(R*)C(O)N(R*)2 and —OR*;
- or
- R3 and R4 taken together with the carbon to which they are attached form C═O, or a 3-8 membered saturated, partially saturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from the groups consisting of O, N, and S, wherein the ring is optionally and independently substituted with one or more selected from the group consisting of ═O, ═S, ═N—R*, C1-10 aliphatic, C1-10 haloaliphatic, halogen, —CN, —NO2, —N(R*)2, —S(O)pR*, —S(O)pNR*, —C(O)N(R*)2, —NR*C(O), —OC(O)N(R*)2, —N(R*)C(O)OR*, —N(R*)C(O)N(R*)2 and —OR*;
- each R5 and R6 are independently —H, halogen, C1-10 haloaliphatic, or C1-10 aliphatic;
- each R7 is independently C1-10 haloaliphatic, C1-10 aliphatic, halogen, —NO2, —(CR++2)nCN, —(CR++2)nN(R**)2, —(CR++2)nOR**, or —(CR++2)nC(O)N(R**)2, or two R7 groups together with the carbon to which they are attached form C═O;
- each R++ is independently —H or halogen;
- each R* is independently —H or C1-10 alkyl or aralkyl optionally and independently substituted with up to five halogen groups;
- each R** is independently —H or C1-10 alkyl optionally and independently substituted with up to five halogen groups;
- each n is independently 0, or 1-10;
- and
- each p is independently 0, 1, or 2.
12 more elements
A compound represented by a structural formula selected from the group consisting of:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- or a pharmaceutically acceptable salt thereof.
15 more elements
Dependencies are inferred from the claim text.